LYZZ Capital: Funding, Team & Investors | Startup Intros

Loading organizations...

LYZZ Capital: Funding, Team & Investors | Startup Intros

Financial History

Total Raised

N/A

Valuation

N/A

Investments Made

Date	Company	Round	Lead Investor(s)	Co-Investor(s)
Nov 7, 2025	Onchilles Pharma	$25.0M Series A	—	InVivium Capital, Kennedy Lewis Investment Management, Lincoln Park Capital, University of Chicago Medicine
Aug 28, 2025	Wugen	$115.0M Other Equity	Fidelity Management & Research Company	Abingworth, Aisling Capital, Intermediate Capital Group, Lightchain Capital, Niall O'Donnell, Tybourne Capital Management
Jun 1, 2022	MojiaBio	$80.0M Series B	Temasek	BASF Venture Capital, Bits x Bites, Bo Bai, Sento Investment
Dec 1, 2021	OncoMyx Therapeutics	$50.0M Series B	B Capital Group, Benjamin Rovinski, Ph.D.	Boehringer Ingelheim, City Hill Ventures, Delos Capital, Korea Investment Partners, Madison Partners, Xeraya Capital
Jul 1, 2021	Wugen	$170.0M Series B	Abingworth, Bosun Hau	RiverVest, Aisling Capital, Alexandria Venture Investments, Falcon Edge Capital, Fidelity Management & Research Company, Peter Kiener, Lightchain Capital, John McKearn, Sands Capital, Velosity Capital
Jun 10, 2021	Onchilles Pharma	$7.0M Series A	Court R. Turner	University of Chicago
Mar 11, 2021	Neurelis	$114.0M Series D	—	Cormorant Asset Management, Decheng Capital, HBM Healthcare Investments, Philos & Partners
Feb 19, 2021	Jumpcode Genomics	$21.0M Series B	Arboretum Ventures, Michael Liang	—
Oct 22, 2018	Qpex Biopharma	$33.0M Series A	Carol Gallagher	Adams Street Partners, Biomedical Advanced Research and Development Authority, Hatteras Venture Partners, Stanford University
Jun 1, 2018	Alpha Biopharma	$37.0M Series A	Qiming Venture Partners	TF Fund